Hyperlipoproteinemias:
Indications for EVKEEZA:
Adjunct to other LDL-C lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
Safety and efficacy have not been established for other causes of hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Effects on cardiovascular morbidity and mortality have not been determined.
Adult Dosage:
Give by IV infusion over 60mins. ≥12yrs: 15mg/kg once monthly (every 4 weeks).
Children Dosage:
<12yrs: not established.
EVKEEZA Warnings/Precautions:
Discontinue if serious hypersensitivity reactions occur; monitor and treat appropriately. Assess LDL-C when clinically appropriate; effects may be measured as early as 2 weeks after initiation. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for at least 5 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers.
EVKEEZA Classification:
Angiopoietin-like 3 (ANGPTL3) inhibitor.
Adverse Reactions:
Nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, nausea; hypersensitivity reactions.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial (2.3mL, 8mL)—1
